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Abstract: Renal safety of selective COX-2 inhibitors (coxibs) is a matter of ongoing discussion. Therefore,
in the present study we examined the effects of two different coxibs, celecoxib and rofecoxib, compared
to a traditional NSAID, diclofenac, and placebo in salt-sensitive hypertension. Salt-sensitive (DS) and
salt-resistant (DR) Dahl rats were fed with NaCl enriched diet (4% NaCl) for 8 weeks. Diclofenac (DS-
diclofenac), rofecoxib (DS-rofecoxib), celecoxib (DS-celecoxib) or placebo were added to chow from week
6 to 8. Immunostaining for monocytes/macrophages (ED1) and cytotoxic T-lymphocytes (CD8) was
performed. In addition, renal morphology and proteinuria were assessed. COX-2 protein and mRNA
were isolated from renal cortex. Untreated hypertensive animals showed preglomerular and glomerular
injury including endothelial activation/proliferation, broadened adventitia, collapsing glomerulopathy,
mesangial sclerosis, mesangiolysis, extracapillary proliferation, protein drops and especially high grade
of glomerulosclerosis (p<0.05 vs DR-placebo) and CD8 and ED1 positive cells (p<0.01 vs DR-placebo)
which was improved by celecoxib but not by diclofenac and rofecoxib. Proteinuria was observed in
hypertensive animals (p<0.0001 vs DR-placebo), normalised by celecoxib (p=0.0015 vs DS-placebo) and
increased by rofecoxib (p<0.05 vs DS-placebo). COX-2 protein and mRNA levels were comparable in all
groups. Renal function and morphology improves after celecoxib but not after rofecoxib or diclofenac.
This head-to-head comparison demonstrates differential effects of coxibs on renal morphology and function
in salt-dependent hypertension
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with mild rise of creatinine levels. The aim of this study is to Know the
prevalence and significance of hypertension patients nephropathy.
Patients and Methods: Descriptive and transversal study with hyper-
tensive patients attended at first time in an Hypertension Unit from 1997
to june 2004. Samples to determine serum creatinine level and urinary
protein level were obtained. Other cardiovascular risk factors were de-
tected.
Results: 1167 patients were included in the study. Mean age was
54,2914,34 (40,9% male). Creatinine level over 1,2 mg/dl was found in
240 patients. Mean variable of patients were: male (72,5%; p0.0001)
(OR 5.42 3,96-7.43), age (58  14,4 vs 53,3214,17 year old; p
0.0001), uric acid (7,11,2 vs 5,521,54 mg% p0.0001), total cho-
lesterol, LDL cholesterol, triglycerides, smokers and microalbuminuria.
All of them have more organ damage: ischemic cardiopathy and cerebral
arterial disease (10.4% vs 4,5% (p0.0001) OR 2.45 ( 1.46-4.10), and
retinopathy.
Conclusion: Prevalence of mild renal failure in hypertensive patients
is high. These patients also have more organ damage.
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RENAL INSUFFICIENCY IS THE MOST PREVALENT
TARGET-ORGAN DISEASE IN PRIMARY CARE-
ATTENDED ESSENTIAL HYPERTENSION
Manuel Gorostidi, Miguel A Prieto, Rafael Marin,
Alba Riesgo, Salvador Tranche. Nephrology, Hospital de Jarrio,
Jarrio, Asturias, Spain; Primary Care, Centro de Salud Vallobin,
Oviedo, Asturias, Spain; Nephrology, Hospital Central de Asturias,
Oviedo, Asturias, Spain; Primary Care, Centro de Salud El Cristo,
Grupo Oviedo Hipertension, Oviedo, Asturias, Spain.
The JNC 7 report included an estimated glomerular filtration rate (eGFR)
60 ml/min/1.73 m2 within target-organ diseases. The aim of the present
study was to assess the prevalences of target-organ damages in a broad
sample of hypertensive patients.
A multicenter, cross-sectional observation of unselected patients with
treated essential hypertension attending primary health centers was per-
formed between January and September 2003. Prevalences of target-
organ diseases were evaluated. Renal function was estimated by Levey
equation. An eGFR 60 ml/min/1.73 m2 was considered as renal insuf-
ficiency (RI).
Data from 2,517 patients were analyzed, 61.3% female. Mean age was
69.1  12 years. Mean systolic BP was 139  16 mmHg and mean
diastolic BP pressure was 79  9 mmHg. Prevalences of target-organ
diseases were: RI 36.9%, coronary heart disease (CHD) 12.7%, left
ventricular hypertrophy 12.5%, stroke 8.9%, heart failure (HF) 5.6%, and
peripheral arterial disease (PAD) 4.4%. RI was the most frequent target-
organ disease within men (24.9% vs CHD 15.8%, stroke 11.4%, HF
5.5%, and PAD 7.7%) and women (44.4% vs CHD 10.9%, stroke 7.4%,
HF 5.8%, and PAD 2.3%), and within patients aged 40 to 59 years (7.1%
vs CHD 5.0%, stroke 3.4%, HF 1.1%, and PAD 0.9%), 60 to 69 years
(32.6% vs CHD 10.2%, stroke 5.7%, HF 2.9%, and PAD 3.4%), and 70
or more years (50.9% vs CHD 16.8%, stroke 12.6%, HF 8.5%, and PAD
6.3%). Percentage of patients with RI but without cardiovascular disease
or diabetes, mentioned as candidates for secondary prevention, was
19.9%.
Renal disease is simultaneously a major risk factor and a target-organ
disease highly prevalent in hypertensive patients followed at the primary
care level. RI can be an associated condition more prevalent than classic
target-organ diseases especially in the elderly. Adequate screening of
renal impairment, as recommended by recent guidelines, must be at the
basis of risk stratification and target-organ disease assessment.
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Matthias Hermann, Sidney Shaw, Thomas F Luscher,
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Zurich, Zurich, Switzerland; Department of Clinical Research,
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and Molecular Pathology, German Cancer Research Center,
Heidelberg, Germany.
Renal safety of selective COX-2 inhibitors (coxibs) is a matter of
ongoing discussion. Therefore, in the present study we examined the
effects of two different coxibs, celecoxib and rofecoxib, compared to a
traditional NSAID, diclofenac, and placebo in salt-sensitive hyperten-
sion.
Salt-sensitive (DS) and salt-resistant (DR) Dahl rats were fed with
NaCl enriched diet (4% NaCl) for 8 weeks. Diclofenac (DS-diclofenac),
rofecoxib (DS-rofecoxib), celecoxib (DS-celecoxib) or placebo were
added to chow from week 6 to 8. Immunostaining for monocytes/
macrophages (ED1) and cytotoxic T-lymphocytes (CD8) was performed.
In addition, renal morphology and proteinuria were assessed. COX-2
protein and mRNA were isolated from renal cortex.
Untreated hypertensive animals showed preglomerular and glomer-
ular injury including endothelial activation/proliferation, broadened
adventitia, collapsing glomerulopathy, mesangial sclerosis, mesangi-
olysis, extracapillary proliferation, protein drops and especially high
grade of glomerulosclerosis (p0.05 vs DR-placebo) and CD8 and
ED1 positive cells (p0.01 vs DR-placebo) which was improved by
celecoxib but not by diclofenac and rofecoxib. Proteinuria was ob-
served in hypertensive animals (p0.0001 vs DR-placebo), nor-
malised by celecoxib (p0.0015 vs DS-placebo) and increased by
rofecoxib (p0.05 vs DS-placebo). COX-2 protein and mRNA levels
were comparable in all groups.
Renal function and morphology improves after celecoxib but not after
rofecoxib or diclofenac. This head-to-head comparison demonstrates
differential effects of coxibs on renal morphology and function in salt-
dependent hypertension.
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DIFFERENTIAL REGULATION OF ACE2 GENE
EXPRESSION IN THE HEART AND KIDNEY OF
NORMOTENSIVE RATS
Jessup Jewell, Gallagher E Patricia, Chappell C Mark,
Tallant E Ann, Ferrario M Carlos. Hypertension and Vascular
Disease Center, Wake Forest University School of Medicine, Winston
Salem, NC.
ACE2, a recently described homologue of ACE, catalyses the cleav-
age of angiotensin II (Ang II) into the vasodilator, natriuretic, and
anti-proliferative peptide angiotensin-(1-7) [Ang-(1-7)]. The role of
Ang-(1-7) as a cardio-renal protective hormone was further illumi-
nated by our demonstration that blockade of type 1 Ang II receptors
(AT1-R) in Lewis rats caused a 3-fold upregulation of cardiac ACE2
mRNA paralleled with increased plasma Ang-(1-7) levels and reversal
of heart failure post-myocardial infarction (Ishiyama et al. Hyperten-
sion 43: 970-976, 2004). The demonstration that blockade of the
AT1-R modulates cardiac ACE2 gene expression raised the question
whether the same effect may be produced in the kidney where ACE2
gene expression is high and Ang-(1-7) is critically involved in the
control of renal function. Thirty-six male 10 wk old normotensive
Lewis rats received vehicle, lisinopril, losartan, or both drugs in
combination in the drinking water for 12 days (10/mg/kg/day for each
of the agents). Combination therapy (lisinopril  losartan) produced
the largest decrease in tail-cuff systolic blood pressure (- 41 mm Hg)
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